Navigation Links
Booster dose not required for Hepatitis B Vaccination

Alessandro Remo Zanetti and his colleagues from Institute of Virology, Italy has found that Initial vaccination with Hepatitis B produces the required concentrations of circulating antibodies in the blood of the patients for long periods//. The researchers have found that the circulating antibodies against Hepatitis B vaccination are present in the blood for at least 10 years after vaccination. Researchers have concluded that there is no need of booster doses of Hepatitis B in these patients as enough amount of antibodies are present which can give protection in case of Hepatitis B infection. The results of the work have been published in the journal The Lancet.

Viral hepatitis B is a leading cause of acute and chronic liver disease worldwide. The World Health Organization (WHO) estimates that, globally, about 2 billion people have been infected with hepatitis B virus (HBV). More than 350 million people are chronically infected. WHO recommends that all countries should have universal infant or adolescent hepatitis B vaccination integrated into their national immunization programs.

The researchers conducted their trial in 1212 children’s and 446 Italian Air Force Recruits by vaccinating with Hepatitis B vaccination. They found that 64% of children and 89% of the recruits retained protective concentrations of antibodies. The study shows that infant and adolescent immune systems can recall responding to hepatitis B more than 10 years after immunization.

Experts View:

Professor Zanetti concludes: “In light of our findings, the use of routine booster doses of hepatitis B vaccine does not seem necessary to maintain long-term protection in immuno-competent individuals vaccinated as infants and teenagers."

Ding-Shinn Chen, National Taiwan University, Taiwan said, “Unless accumulating data show a significant increase of HBV infection in adolescents or adults who were vaccinated as children, a policy of booster vaccination in a population should not be recommended. We believe that this applies both to hyper-endemic and low endemic areas of the world.”

Source: News wise, The Lancet

Related medicine news :

1. Need for Hepatitis Booster Questioned
2. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
3. Booster Dose for Chickenpox Vaccine Recommended
4. Care for footwear not required diabetic patients
5. Advanced STD programs required
6. New Stem Cells lines will be required
7. Multi targeted approach required for suicide prevention in adolescents
8. More Funds required for Asian Countries to fight Bird Flu
9. Clergy blasts councilmans required-condom plan
10. Salmeterol - to be used in combination & only when required
11. Vitamin B for Hepatitis
Post Your Comments:

(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: